Recently, GB19 Injection, independently developed by Shenzhen Kexing Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Kexing Biopharm, has officially received an Investigational New Drug (IND) approval notice from the U.S. Food and Drug Administration (FDA), allowing clinical trials to be conducted in the United States. The indication is for the treatment of cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).
Regulatory Approval Details
Drug name: GB19 Injection
Application purpose: Conduct clinical trials in the United States
Application number: IND 180417
Review conclusion: The FDA has approved the IND application for this investigational drug and agreed that clinical studies may be conducted in accordance with the submitted protocol.
Drug Overview
GB19 Injection targets BDCA2, a receptor specifically expressed on the surface of plasmacytoid dendritic cells (pDCs). Its mechanism of action is distinct from that of currently approved therapies that primarily targeting the B-cell pathway. By specifically binding to BDCA2, GB19 inhibits the production of type I interferon by pDC cells, thereby modulating the pathogenic feedback loops between innate and adaptive immunity.
In preclinical studies ,GB19 demonstrated high potency, favorable bioavailability, sustained target inhibition for over 90 days, low immunogenicity, and an excellent safety profile. If successfully developed, it is expected to provide a new treatment options for patients with autoimmune diseases associated with interferon pathway dysregulation including SLE.
Lupus erythematosus is a serious autoimmune disease that significantly affects human health, with a large global patient population and a strong unmet clinical need for safer and more effective innovative therapies. Previously, this project had already been approved for clinical trials by the National Medical Products Administration (NMPA) in China.
GB19 adopts a simultaneous submission strategy in both China and the United States, marking an important breakthrough in the company’s innovation-driven R&D and global expansion in the autoimmune field. In addition to GB19, several innovative drug programs such as GB05 (human interferon inhalation solution) and GB18 (cancer cachexia treatment) have also achieved dual IND filings in China and the U.S., demonstrating the continuous execution of Kexing Biopharm’s “innovation + globalization” strategy.
https://www.kexingbiopharm.com/
Kexing Biopharm
